Sanofi, Janssen partner on potential E. coli pathogenic vaccine
According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Oct 23
According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
03 Oct 23
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule
03 Oct 23
The agreement expands the companies' existing relationship, which entails collaborating on IND-enabling preclinical studies for IAMA-6
28 Sep 23
The Swiss pharmaceutical firm will obtain exclusive global rights to develop, manufacture, and market the medicines by making…
26 Sep 23
Valo will receive an upfront payment and a potential near-term milestone payment, totalling $60m, and is eligible to…
25 Sep 23
Under the expanded partnership, scientists at the ICR’s Centre for Cancer Drug Discovery will work with researchers at…
22 Sep 23
Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform to discover and develop innovative therapies by applying…
21 Sep 23
Everest will obtain exclusive rights to develop and commercialise zetomipzomib in Greater China, South Korea, and other South…
21 Sep 23
Under the licensing agreement, RefleXion will develop and commercialise RXM-4768 molecule to direct its SCINTIX biology-guided radiotherapy
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Sep 23
Under the partnership, both parties will discover novel small molecule drugs using Orionis’s Allo-Glue platform for challenging targets…